Coskun Ozer Demirtas
Overview
Explore the profile of Coskun Ozer Demirtas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demirtas C, Yilmaz Y
J Clin Transl Hepatol
. 2024 Oct;
12(10):857-864.
PMID: 39440221
Chronic liver disease (CLD) represents a significant global health burden, with hepatic steatosis-associated disorders-such as metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease, and hepatitis C virus infection-being major contributors. Recent...
2.
Ergenc I, Kara E, Yilmaz M, Demirtas C, Keklikkiran C, Das T, et al.
Heliyon
. 2024 Aug;
10(15):e34915.
PMID: 39144976
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global epidemic in Türkiye and worldwide. The aim of this study was to evaluate the prevalence and predictors...
3.
Kadioglu D, Demirtas C, Pirim D, Dilber F, Eren F
Hepatol Forum
. 2024 Jul;
5(3):106-112.
PMID: 39006138
Background And Aim: It is reported that miRNAs play an important role in hepatocellular carcinogenesis and may serve as non-invasive biomarkers for hepatocellular carcinoma (HCC). MiR-4510 and miR-146b-5p expression levels...
4.
Demirtas C, Eren F, Yilmaz D, Ozdogan O, Gunduz F
J Gastrointestin Liver Dis
. 2024 Jun;
33(2):203-211.
PMID: 38944871
Background And Aims: Progression to hepatocellular carcinoma (HCC) is restricted by viral suppression in chronic hepatitis B (CHB); however, some patients still progress despite antiviral therapy. Presence of single nucleotide...
5.
Degirmencioglu Tosun S, Demirtas C
Turk J Gastroenterol
. 2023 Jun;
34(6):672.
PMID: 37303247
No abstract available.
6.
Mutis Alan A, Alan O, Asadov R, Demirtas C, Kani H, Yumuk P, et al.
Hepatol Forum
. 2023 May;
4(2):53-60.
PMID: 37250924
Background And Aim: Transarterial Chemoembolization (TACE) therapy is currently considered as first option therapy in the intermediate stage HCC. The purpose of our study is to assess the efficacy and...
7.
Cimsit C, Kursun M, Demircioglu O, Dilber F, Demirtas C, Ergenc I
Acad Radiol
. 2023 Apr;
30 Suppl 1:S124-S131.
PMID: 37012127
Rationale And Objectives: To define sarcopenic obesity (SaO) among chronic liver disease (CLD) patients via CT and MRI, and assess its impact on liver disease severity. Materials And Methods: CLD...
8.
Guzelbulut F, Karaogullarindan U, Akkiz H, Altintas E, Demirtas C, Bahadir O, et al.
Hepatol Forum
. 2022 Sep;
3(3):71-76.
PMID: 36177097
Background And Aim: The aim of the present study was to examine the etiology of hepatocellular carcinoma (HCC) by underlying cause and determine the characteristics and clinical features of patients...
9.
Demirtas C, Ricco G, Ozdogan O, Baltacioglu F, Ones T, Yumuk P, et al.
Hepatol Commun
. 2022 Sep;
6(12):3600-3601.
PMID: 36125257
No abstract available.
10.